Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Johannes LorscheiderJ KuhleG IzquierdoA LugaresiE HavrdovaD HorakovaR HuppertsP DuquetteM GirardA PratF Grand'MaisonP GrammondP SolaD FerraroM TrojanoC Ramo-TelloJ Lechner-ScottE PucciC SolaroM SleeV Van PeschJ L Sanchez MenoyoA van der WaltH ButzkuevenL KapposTomas Kalinciknull null

Published in: European journal of neurology (2018)

Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.

Keyphrases

multiple sclerosis
anti inflammatory
white matter
preterm infants
type diabetes
gestational age
combination therapy
skeletal muscle
insulin resistance